Termination by Genentech. Genentech may terminate this Agreement without cause, effective no earlier than twelve (12) months after the Effective Date upon six (6) months’ prior written notice to Curis of such termination. Genentech may also terminate this Agreement solely with respect to one or more: specific Compound, delivery system for a Compound (i.e., Systemic Delivery or topical delivery) and/or indication for which a Compound may be used and/or the country(ies) in which a Compound may be developed and commercialized. Any such termination is permitted no earlier than twelve (12) months after the Effective Date upon six (6) months’ prior written notice and the Agreement shall thereafter be read and interpreted in light of such termination(s).
Termination by Genentech. 34 4. Termination of Development/Commercialization...............35 5.
Termination by Genentech. GENENTECH may terminate the Co-promotion ------------------------ Term upon the occurrence of any of the following: [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Termination by Genentech. (a) If ROCHE fails to exercise its "best efforts" to commercialize a Product in a country in the Roche Territory, GENENTECH shall have the right to request ROCHE to take remedial measures. If GENENTECH makes such a request and ROCHE thereafter does not exercise such "best efforts" within a period of six (6)
Termination by Genentech. Genentech shall have the right to terminate this Agreement in its entirety, in its sole discretion, upon [ * ] written notice to Array.
Termination by Genentech. (i) In the event that Genentech terminates this Agreement pursuant to Section 10.2, and subject to Sections 10.5(c) and (d), all rights and licenses granted by Array hereunder with respect to Compounds and Licensed Products shall immediately terminate.
Termination by Genentech. Subject to Section 18.3(c) below, Genentech may terminate this Agreement with respect to itself (including, without limitation, its rights and obligations after the effective date of such termination, subject to the provisions of Section 18.6), at any time after the date which is *****, by giving ***** prior written notice to Novartis and Tanox and paying all amounts it is financially responsible for hereunder up to such termination date; provided, however, such notice shall not be deemed delivered hereunder unless and until Genentech gives written notice of termination of the JCA to Novartis, with a copy to Tanox; and provided, further, that within ***** of receipt of such notice, Novartis and Tanox may, by giving joint notice to Genentech accelerate the effective date of any such termination to a date not less than ***** from the date of Genentech’s notice of termination under this Section18.3(a). *****
Termination by Genentech. Genentech shall have the right to terminate the license granted pursuant to this Agreement, in its entirety (or as to any Licensed Product in any country in the Territory), at any time (or from time to time), in any case of at least six (6) months' advance notice to Alteon. Such termination shall be effective six (6) months from the effective date of such notice, and all Genentech's rights and duties associated therewith shall cease as of that date, subject to Sections 10.7-10.10.
Termination by Genentech. If Genentech terminates this Agreement for cause under Section 10.5.1 or 10.5.2 then the following shall apply:
Termination by Genentech. (a) If ROCHE fails to exercise its "best efforts" to commercialize a Product in a country in the Roche Territory, GENENTECH shall have the right to request ROCHE to take remedial measures. If GENENTECH makes such a request and ROCHE thereafter does not exercise such "best efforts" within a period of six (6) months after GENENTECH has requested ROCHE to take remedial measures or if ROCHE fails to meet the requirements of Article III, Section 6, then GENENTECH shall have the right (x) to terminate ROCHE's license hereunder with respect to such country if Registration for the Product has not been initiated or (y) to convert the license to a nonexclusive one if Registration has been initiated and
